S0702: A Prospective Observational Multicenter Cohort Study To Assess The Incidence of Osteonecrosis Of The Jaw (ONJ) In Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Aims: Zoledronic acid is a drug that can reduce bone pain and lower the chances of broken bones in patients who have cancer that has spread to their bones. Usually, zoledronic acid is well tolerated by patients, but it has been associated with an increase in the number of reported cases of osteonecrosis of the jaw (ONJ), condition that can cause swelling, infection, loose teeth, drainage and jaw bone exposure. The purpose of this study is to learn how often ONJ occurs in patients who are being treated with zoledronic acid during a 3 year time period after starting treatment. This study will also identify risk factors associated with ONJ.
Diagnosis: Bone Metastases
Principal Investigator: Elaine Wade, MD
IRB Approval Number: EH09-229
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research coordinator Nancy Haefling at 847.657.5957 or research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

× Alternate Text